Literature DB >> 33811719

Correction.

.   

Abstract

Year:  2021        PMID： 33811719      PMCID： PMC8019208          DOI： 10.1111/cas.14818

Source DB:  PubMed          Journal:  Cancer Sci        ISSN： 1347-9032            Impact factor:   6.716


× No keyword cloud information.
  1 in total

1.  A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.

Authors:  Naohiro Sekiguchi; Shinya Rai; Wataru Munakata; Kenshi Suzuki; Hiroshi Handa; Hirohiko Shibayama; Tomoyuki Endo; Yasuhito Terui; Noriko Iwaki; Noriko Fukuhara; Hiro Tatetsu; Shinsuke Iida; Takayuki Ishikawa; Ryota Shiibashi; Koji Izutsu
Journal:  Cancer Sci       Date:  2020-07-20       Impact factor: 6.716
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.